Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P; STAR SIGN Study Investigators; Albrich WC, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Aliment Pharmacol Ther. 2023 Oct;58(7):678-691. doi: 10.1111/apt.17661. Epub 2023 Aug 12. Aliment Pharmacol Ther. 2023. PMID: 37571863
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P; STAR SIGN Study Investigators; Friedrich M, Misselwitz B, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28. Aliment Pharmacol Ther. 2023. PMID: 36307899 Free PMC article.
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Leinenkugel G, Graf N, Krieger C, Truniger S, Franke A, Koller S, Metzger-Peter K, Oberholzer M, Frei N, Geissler N, Schaub P, Star Sign Investigators, Albrich WC, Friedrich M, Niess JH, Schneiderhan-Marra N, Dulovic A, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Vaccines (Basel). 2024 Jul 15;12(7):774. doi: 10.3390/vaccines12070774. Vaccines (Basel). 2024. PMID: 39066413 Free PMC article.
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N; STAR SIGN Study Investigators; Albrich WC, Friedrich M, Niess JH, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi JJ, Brand S. Woelfel S, et al. Aliment Pharmacol Ther. 2024 Oct 29. doi: 10.1111/apt.18349. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39468971
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Kammerlander L, Häuptle R, Zwyssig S, Krieger C, Truniger S, Koller S, Metzger-Peter K, Frei N, Star Sign Study Investigators, Albrich WC, Friedrich M, Bernsmeier C, Niess JH, Korte W, Bürgi JJ, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. Woelfel S, et al. Vaccines (Basel). 2024 Oct 31;12(11):1241. doi: 10.3390/vaccines12111241. Vaccines (Basel). 2024. PMID: 39591144
49 results